Beyond Xeljanz: An inflammation & immunology portfolio blooms at Pfizer (Pink Sheet - Informa) - Dec 23, 2013 - “Pfizer is…hoping that pipeline drugs, including next-generation JAKs, will stand out by addressing unmet medical need in indications like lupus…and inflammatory bowel disease….Pfizer is testing the IL-6 inhibitor for Crohn’s and lupus in Phase II tests.”; Company is also studying JAK1 inhibitor in lupus.
Pipeline update • Immunology • Inflammatory Bowel Disease • Lupus
|
|
A subscription to The Pink Sheet is required to access this article
|